A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-361
- Sponsors Merck Sharp & Dohme
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 28 Mar 2017 Planned End Date changed from 1 Apr 2020 to 28 Mar 2020.
- 28 Mar 2017 Planned primary completion date changed from 1 Mar 2019 to 29 Jan 2019.